Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $51,150.00. Following the sale, the insider owned 1,346,053 shares in the company, valued at $13,770,122.19. This trade represents a 0.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Pieper also recently made the following trade(s):
- On Thursday, October 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total value of $47,050.00.
- On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00.
- On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.
Xeris Biopharma Stock Performance
NASDAQ XERS opened at $10.46 on Thursday. Xeris Biopharma Holdings, Inc. has a 52-week low of $5.25 and a 52-week high of $11.41. The company has a 50-day simple moving average of $9.40 and a 200 day simple moving average of $7.55. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The company has a market capitalization of $1.91 billion, a PE ratio of -95.09 and a beta of 0.61.
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The company had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. On average, research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. GK Wealth Management LLC purchased a new position in Xeris Biopharma during the third quarter worth about $32,000. Allworth Financial LP purchased a new stake in shares of Xeris Biopharma in the 2nd quarter valued at about $34,000. KBC Group NV bought a new stake in shares of Xeris Biopharma during the 1st quarter valued at about $27,000. William Mack & Associates Inc. bought a new stake in shares of Xeris Biopharma during the 3rd quarter valued at about $53,000. Finally, Sterling Capital Management LLC grew its holdings in shares of Xeris Biopharma by 848.0% during the third quarter. Sterling Capital Management LLC now owns 5,707 shares of the company’s stock worth $55,000 after purchasing an additional 5,105 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have issued reports on XERS shares. Barclays raised their target price on Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 6th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Finally, Leerink Partners lifted their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.20.
Get Our Latest Stock Analysis on XERS
Xeris Biopharma Company Profile
Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.
Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.
Read More
- Five stocks we like better than Xeris Biopharma
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
